•
BY
BYSI
BeyondSpring Inc. Ordinary Shares
yahooPHARMACEUTICAL PREPARATIONS
--
Price Chart
Market Cap
68.67M
Volume
25.89K
52W High
$3.44
52W Low
$0.98
Open
$0.00
Prev Close
$1.70
Day Range
0.00 - 0.00
About BeyondSpring Inc. Ordinary Shares
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.
Latest News
BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path
GlobeNewswire Inc.•Dec 12
SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors
GlobeNewswire Inc.•Jan 28
BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies
GlobeNewswire Inc.•Jan 28
BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting
GlobeNewswire Inc.•Nov 11
BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024
GlobeNewswire Inc.•Sep 16
BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin
GlobeNewswire Inc.•Sep 3
BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics
GlobeNewswire Inc.•May 3
BeyondSpring Files 2023 Annual Report on Form 20-F
GlobeNewswire Inc.•Apr 29